Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 926 Neoplasms 609 Breast Neoplasms 604 Colorectal Neoplasms 457 Neoplasm Metastasis 394 Ovarian Neoplasms 328 Melanoma 312 Prostatic Neoplasms 311 Lung Neoplasms 294 Multiple Myeloma 290 Recurrence 278 Squamous Cell Carcinoma of Head and Neck 246 Stomach Neoplasms 229 Pancreatic Neoplasms 228 Leukemia, Myeloid, Acute 220 Triple Negative Breast Neoplasms 190 Endometrial Neoplasms 190 Carcinoma, Renal Cell 182 Lymphoma, Non-Hodgkin 179 Carcinoma, Hepatocellular 177 Small Cell Lung Carcinoma 165 Leukemia, Lymphocytic, Chronic, B-Cell 156 Advanced Solid Tumors 154 Lymphoma, Follicular 148 Urinary Bladder Neoplasms 139 Lymphoma, Large B-Cell, Diffuse 138 Lymphoma 137 Advanced Solid Tumor 137 Uterine Cervical Neoplasms 134 Head and Neck Neoplasms 134

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Cancer Recurrent × 1 year × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡